ORIC Pharmaceuticals announced the selection of the Phase 3 dose for rinzimetostat, a prostate cancer drug, and plans to start the Himalayas-1 global registrational trial in the first half of 2026. Early data show rinzimetostat has a strong safety profile and promising efficacy compared to current treatments for metastatic castration-resistant prostate cancer (mCRPC). The company also reported progress with enozertinib for lung cancer and expects multiple clinical updates later in 2026. With $420 million in cash, ORIC is well-funded to support operations into late 2028 and aims to become a multi-asset oncology company.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...
Law Offices of Howard G. Smith has announced upcoming deadlines for investors to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege that the compani...
The global waterborne epoxy resins market, valued at $4.98 billion in 2024, is projected to grow at a CAGR of 6.03% to $8.51 billion by 2034. This growth is fueled by strict international regulations targeting volatile organic compound emissions and ...
NEWMEDIA.COM highlights that top ecommerce web design agencies prioritize conversion and scale over just appearance, addressing the nearly 70% cart abandonment rate largely caused by fixable user experience issues like slow pages and complicated chec...
